Clinical Trials Logo

Clinical Trial Summary

To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).


Clinical Trial Description

This is a 114-week,randomized, multicenter, double-blind, parallel-group, active-control study with an open-label extension period of up to 156 weeks, for a total duration of up to 270 weeks in patients with IgAN who have persistent overt proteinuria and remain at high risk of disease progression despite being on a stable dose (or doses) of an angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) that is (are) a maximum tolerated dose that is at least one half of the maximum labeled dose (MLD) (according to approved labeling. Approximately 380 patients aged ≥18 years will be enrolled in the study globally. The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor antagonist. The active control is irbesartan. The purpose of the study is to evaluate the potential benefit of sparsentan on kidney function by analyzing change in proteinuria (protein in urine) and estimated glomerular filtration rate (eGFR) as compared to current standard treatment. Patients enrolled in the PROTECT study (Protocol 021IGAN17001) will be those at high risk of progressing to renal failure. They will be randomly assigned in a 1:1 ratio to either sparsentan or irbesartan, as the active control (current standard treatment) at the Day 1 (Randomization) visit. Study medication (sparsentan and irbesartan) will be administered as a single oral morning dose. The primary analysis is change in proteinuria (urine protein/creatinine ratio) from baseline at Week 36 in sparsentan-treated patients as compared to irbesartan-treated patients. Primary completion date represents the anticipated completion date of the double-blind portion of the study. Study completion date represents the anticipated completion date of the open-label extension portion of the study. Patients participating in the open-label extension period may be evaluated for eligibility to participate in a randomized, open-label, controlled Sub study evaluating the safety and efficacy of an SGLT2 inhibitor in addition to stable sparsentan treatment (OLE Sub study). The SGLT2 inhibitor, dapagliflozin will be provided as "study medication" for the OLE Sub study. Following completion of the visit 12 weeks after the OLE baseline visit, eligible patients may receive open-label dapagliflozin for at least 12 weeks but up to 24 additional weeks, or through the end of the open-label extension period, whichever is shortest. Approximately 60 patients from the open-label extension period will be enrolled into the OLE Sub study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03762850
Study type Interventional
Source Travere Therapeutics, Inc.
Contact
Status Active, not recruiting
Phase Phase 3
Start date December 11, 2018
Completion date July 2026

See also
  Status Clinical Trial Phase
Completed NCT03719443 - First in Human Study to Assess Safety of VIS649 in Healthy Subjects Phase 1
Terminated NCT05162066 - BCX9930 for the Treatment of C3G, IgAN, and PMN (RENEW) Phase 2
Enrolling by invitation NCT05132621 - The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.
Recruiting NCT05856760 - A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN Phase 2
Recruiting NCT04662723 - Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Phase 4
Completed NCT02384317 - Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade Phase 2
Recruiting NCT05732402 - An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases Phase 1/Phase 2
Active, not recruiting NCT05248646 - Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN) Phase 3
Completed NCT01838239 - Development of a Metabolic Assessment Tool for Chronic Kidney Disease N/A
Recruiting NCT05852938 - A Study of BION-1301 in Adults With IgA Nephropathy Phase 3
Recruiting NCT05834738 - Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy Phase 2
Completed NCT04287985 - Safety and Efficacy Study of VIS649 for IgA Nephropathy Phase 2
Recruiting NCT05097989 - Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Phase 2
Completed NCT05200871 - Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
Active, not recruiting NCT04573920 - Atrasentan in Patients With Proteinuric Glomerular Diseases Phase 2
Withdrawn NCT02605525 - Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy Phase 2
Recruiting NCT04564339 - Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Phase 2
Active, not recruiting NCT04573478 - Atrasentan in Patients With IgA Nephropathy Phase 3
Active, not recruiting NCT04663204 - A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy Phase 2
Recruiting NCT05003986 - Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Phase 2